Purpose Positron emission tomography (PET) after chemotherapy can guide consolidating radiotherapy in advanced-stage Hodgkin lymphoma (HL). This analysis aims to improve outcome prediction by integrating additional criteria derived by computed tomography (CT). Patients and Methods The analysis set consisted of 739 patients with residues > 2.5 cm after chemotherapy from a total of 2,126 patients treated in the HD15 trial (HD15 for advanced stage Hodgkin's disease: Quality assurance protocol for reduction of toxicity and the prognostic relevance of fluorodeoxyglucose-positron-emission tomography [FDG-PET] in the first-line treatment of advanced-stage Hodgkin's disease) performed by the German Hodgkin Study Group. A central panel performed ima...
The use of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) for response assessment in...
The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission...
BACKGROUND: It is unclear whether patients with early-stage Hodgkin's lymphoma and negative findings...
In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron...
Background To investigate the use of positron emission tomography/computed tomography with F-18-fluo...
International audience: PET performed after 2 cycles of chemotherapy (PET2) allows prediction of out...
ObjectivesThe qualitative analysis of interim PET has been reported to be useful for predicting the ...
Negative [(18)F]fluorodeoxyglucose (FDG) -positron emission tomography (PET)/computed tomography (CT...
The FDG-PET method is a standard procedure in staging and response assessment of Hodgkin's lymphoma ...
Objective: Positron Emission Tomography (PET) with F-18-Fluoro-deoxy-glucose (FDG) emerged as a prog...
The HD18 study for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) used positron ...
Given the excellent survival rates for early-stage Hodgkin lymphoma (HL), the young age of many pati...
BACKGROUND AND OBJECTIVES: We explored the predictive value on therapy outcome of an early evaluat...
Our objective was to assess the prognostic value of (18)F-FDG PET after 2 cycles of chemotherapy usi...
PURPOSE Combined-modality treatment (CMT) with 2x ABVD (doxorubicin, bleomycin, vinblastine, and dac...
The use of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) for response assessment in...
The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission...
BACKGROUND: It is unclear whether patients with early-stage Hodgkin's lymphoma and negative findings...
In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron...
Background To investigate the use of positron emission tomography/computed tomography with F-18-fluo...
International audience: PET performed after 2 cycles of chemotherapy (PET2) allows prediction of out...
ObjectivesThe qualitative analysis of interim PET has been reported to be useful for predicting the ...
Negative [(18)F]fluorodeoxyglucose (FDG) -positron emission tomography (PET)/computed tomography (CT...
The FDG-PET method is a standard procedure in staging and response assessment of Hodgkin's lymphoma ...
Objective: Positron Emission Tomography (PET) with F-18-Fluoro-deoxy-glucose (FDG) emerged as a prog...
The HD18 study for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) used positron ...
Given the excellent survival rates for early-stage Hodgkin lymphoma (HL), the young age of many pati...
BACKGROUND AND OBJECTIVES: We explored the predictive value on therapy outcome of an early evaluat...
Our objective was to assess the prognostic value of (18)F-FDG PET after 2 cycles of chemotherapy usi...
PURPOSE Combined-modality treatment (CMT) with 2x ABVD (doxorubicin, bleomycin, vinblastine, and dac...
The use of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) for response assessment in...
The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission...
BACKGROUND: It is unclear whether patients with early-stage Hodgkin's lymphoma and negative findings...